Video

Dr. Dreicer on the Current Role of Abiraterone and Enzalutamide in Prostate Cancer

Robert Dreicer, MD, professor, University of Virginia Health System, discusses the current role of abiraterone acetate (Zytiga) and enzalutamide (Xtandi) for patients with prostate cancer.

Robert Dreicer, MD, professor, University of Virginia Health System, discusses the current role of abiraterone acetate (Zytiga) and enzalutamide (Xtandi) for patients with prostate cancer.

Due to the recognition of cross resistance, clinicians make a judgement to use either abiraterone or enzalutamide as the initial therapy for patients with metastatic castration-resistant prostate cancer. If a patient receives 1 agent, they don’t immediately receive the other because there is a lower likelihood of response.

Clinicians have gotten comfortable using both agents and make decisions based on what they believe is the appropriate drug to use as an initial treatment, taking all toxicities into account.

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center